The factors to consider in outsourcing by a virtual pharmaceutical company were addressed by Zhengming Chen, senior director of chemistry and CMC of Dov Pharmaceutical in his presentation, “Optimized R&D Outsourcing Business Model: From PreClinical to Development: A Case Study,” at Interphex.
Dov Pharmaceutical is a biopharmaceutical company focused on the discovery, acquisition, and development of novel drug candidates for treating disorders of the central nervous system. Dov operates as a virtual company by focusing on discovery of drug candidates and using outsourcing partners to fill its needs in the drug-development process in areas such as lead optimization and medicinal chemistry, process development and manufacturing of active pharmaceutical ingredients, and drug product and clinical packaging.
Even as small company, Chen pointed out that Dov Pharmaceutical uses a global outsourcing strategy and considers and uses partners based in the United States, Europe, and Asia. Globalization of the pharmaceutial industry is often considered in the realm of Big Pharma and the optimization of its development activities and manufacturing networks, but it is also an important part of doing business for the small players. As Big Pharma continues to struggle with product innovation and making its pipeline fertile, meeting the demands of the global virtual pharmaceutical company is an important paradigm in outsourcing.
Share your perspectives in meeting the outsourcing needs by virtual companies and leave a comment below.